FTD has previously been shown to inhibit MYC26, an oncogene known to promote cell cycle progression27, along with members of the E2F-family and downstream E2F targets such as Forkhead Box M1 (FOXM1) and B-Myb (MYBL2)26, both of which are proliferation-associated transcription factors commonly overexpressed in various cancers28,29. This evidence concerns the gene FOXM1 and frontotemporal dementia.